Guardant Health, Inc. (NASDAQ:GH – Get Free Report) insider Terilyn Monroe sold 3,842 shares of the firm’s stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $142.41, for a total transaction of $547,139.22. Following the completion of the sale, the insider directly owned 21,058 shares of the company’s stock, valued at approximately $2,998,869.78. The trade was a 15.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Guardant Health Stock Performance
Shares of GH stock opened at $145.83 on Friday. The stock has a 50 day moving average price of $167.08 and a 200 day moving average price of $133.80. Guardant Health, Inc. has a 52-week low of $74.55 and a 52-week high of $191.05. The firm has a market capitalization of $19.73 billion, a P/E ratio of -39.63 and a beta of 1.67.
Guardant Health (NASDAQ:GH – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.46. The company had revenue of $360.98 million during the quarter, compared to analysts’ expectations of $350.72 million. During the same period in the prior year, the business earned ($0.74) EPS. The company’s quarterly revenue was up 36.1% on a year-over-year basis. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -3.28 EPS for the current year.
Institutional Trading of Guardant Health
Hedge funds have recently bought and sold shares of the stock. Financial Network Wealth Advisors LLC grew its stake in Guardant Health by 17.2% in the third quarter. Financial Network Wealth Advisors LLC now owns 423 shares of the company’s stock valued at $75,000 after purchasing an additional 62 shares during the last quarter. Yousif Capital Management LLC lifted its position in shares of Guardant Health by 6.2% during the third quarter. Yousif Capital Management LLC now owns 1,587 shares of the company’s stock valued at $283,000 after buying an additional 93 shares during the last quarter. Allworth Financial LP lifted its position in shares of Guardant Health by 12.4% during the second quarter. Allworth Financial LP now owns 1,072 shares of the company’s stock valued at $161,000 after buying an additional 118 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Guardant Health by 14.5% in the 2nd quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after buying an additional 122 shares in the last quarter. Finally, Slow Capital Inc. boosted its holdings in shares of Guardant Health by 0.3% in the 3rd quarter. Slow Capital Inc. now owns 52,683 shares of the company’s stock valued at $9,397,000 after buying an additional 136 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.
Wall Street Analyst Weigh In
GH has been the subject of several research analyst reports. Morgan Stanley lifted their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Roth Capital began coverage on Guardant Health in a research report on Thursday, October 22nd. They set a “buy” rating and a $200.00 target price for the company. Stephens reiterated an “overweight” rating and issued a $210.00 target price on shares of Guardant Health in a report on Friday. Rothschild & Co Redburn started coverage on Guardant Health in a research report on Tuesday, September 8th. They set a “buy” rating and a $203.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $191.48.
Read Our Latest Stock Analysis on Guardant Health
Guardant Health News Roundup
Here’s some of the latest news about GH:
- Positive Sentiment: A recent report focused on raised guidance, which may bolster expectations for the company’s business outlook. What raised guidance means for shareholders
- Neutral Sentiment: Insider Terilyn Monroe sold 3,842 shares, reducing her stake by about 15%. The sale was made under a pre-arranged Rule 10b5-1 plan, which makes it a less clear-cut signal about the insider’s view of the company. Insider share sale
- Negative Sentiment: A separate commentary argues that GH looks richly priced after its recent run, raising the risk that valuation could limit further gains. Commentary on Guardant Health’s valuation
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Featured Articles
- Five stocks we like better than Guardant Health
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
